Afinitor (everolimus) - Drug Insight and Market Forecast - 2030

Afinitor (everolimus) - Drug Insight and Market Forecast - 2030

  • August 2020 •
  • 80 pages •
  • Report ID: 5865963 •
  • Format: PDF
Overview
“Afinitor (everolimus) - Drug Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Afinitor (everolimus) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Afinitor (everolimus) is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus’ effect is solely on the mTORC1 protein and not on the mTORC2 protein.Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole, adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease, adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib, adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery, pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. Afinitor for oral administration contains 2.5 mg, 5 mg, 7.5 mg, or 10 mg of everolimus and the following inactive ingredients: anhydrous lactose, butylated hydroxytoluene, crospovidone, hypromellose, lactose monohydrate, and magnesium stearate.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Afinitor (everolimus).
• The report contains historical and forecasted sales for Afinitor (everolimus) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of Afinitor (everolimus).

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Afinitor (everolimus) Analytical Perspective
• In-depth Afinitor (everolimus) Market Assessment
This report provides a detailed market assessment of Afinitor (everolimus) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

• Afinitor (everolimus) Clinical Assessment
The report provides the clinical trials information of Afinitor (everolimus) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Afinitor (everolimus) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Afinitor (everolimus) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to Afinitor (everolimus) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Afinitor (everolimus).
• Our in-depth analysis of the sales data of Afinitor (everolimus) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Afinitor (everolimus) in the market.

Key Questions
• What is the prescribed dosage and strengths of Afinitor (everolimus) are available in the market?
• What are the common adverse reactions or side effects of Afinitor (everolimus)?
• What is the product type, route of administration and mechanism of action of Afinitor (everolimus)?
• What are the chemical specifications of Afinitor (everolimus)?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of Afinitor (everolimus), and what is its future?
• What are the marketed details of Afinitor (everolimus) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to Afinitor (everolimus) and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of Afinitor (everolimus)?
• In which countries Afinitor (everolimus) got approval and when it gets launched?
• What are the clinical trials are currently ongoing for Afinitor (everolimus)?
• How the safety and efficacy results determined the approval of Afinitor (everolimus)?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Afinitor (everolimus) development?
• What are the key designations that have been granted to Afinitor (everolimus)?
• What is the historical and forecasted market scenario of Afinitor (everolimus)?
• How is the market trend of Afinitor (everolimus) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to Afinitor (everolimus)?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?